{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:08:00Z","timestamp":1790204880295,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,14]]},"DOI":"10.1097\/qad.0b013e32834e8955","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T06:23:32Z","timestamp":1321424612000},"page":"167-174","source":"Crossref","is-referenced-by-count":31,"title":["Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy"],"prefix":"10.1097","volume":"26","author":[{"given":"Duncan","family":"Chege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"la Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Raboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Kandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brunetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prameet M.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona R.","family":"Loutfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy.","volume":"387","author":"Perelson","year":"1997","journal-title":"Nature"},{"key":"R2-6-20210130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"R3-6-20210130","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.","volume":"278","author":"Wong","year":"1997","journal-title":"Science"},{"key":"R4-6-20210130","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-6-20210130","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"R6-6-20210130","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1086\/527324","article-title":"Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.","volume":"197","author":"Chun","year":"2008","journal-title":"J Infect Dis"},{"key":"R7-6-20210130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 T cells.","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nature Medicine"},{"key":"R8-6-20210130","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1128\/JVI.79.15.9625-9634.2005","article-title":"Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.","volume":"79","author":"Tobin","year":"2005","journal-title":"J Virology"},{"key":"R9-6-20210130","first-page":"798","article-title":"Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature reviews.","volume":"7","author":"Coiras","year":"2009","journal-title":"Microbiology"},{"key":"R10-6-20210130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00126334-200401010-00004","article-title":"Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.","volume":"35","author":"Ramratnam","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-6-20210130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.","volume":"5","author":"Finzi","year":"1999","journal-title":"Nat Med"},{"key":"R12-6-20210130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature10347","article-title":"Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.","volume":"477","author":"Sigal","year":"2011","journal-title":"Nature"},{"key":"R13-6-20210130","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/518250","article-title":"Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.","volume":"195","author":"Chun","year":"2007","journal-title":"J Infect Dis"},{"key":"R14-6-20210130","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"R15-6-20210130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"Markowitz","year":"2007","journal-title":"J Acquir Immune Deficy Syndr"},{"key":"R16-6-20210130","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e3282f12377","article-title":"Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.","volume":"21","author":"Murray","year":"2007","journal-title":"AIDS"},{"key":"R17-6-20210130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.","volume":"16","author":"Buzon","year":"2010","journal-title":"Nat Med"},{"key":"R18-6-20210130","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/650749","article-title":"Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.","volume":"50","author":"McMahon","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R20-6-20210130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/infdis\/jiq138","article-title":"A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4 T cell response.","volume":"203","author":"Hatano","year":"2011","journal-title":"J Infect Dis"},{"key":"R21-6-20210130","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1086\/514113","article-title":"Simian immunodeficiency virus burden in tissues and cellular compartments during clinical latency and AIDS.","volume":"176","author":"Reinhart","year":"1997","journal-title":"J Infect Dis"},{"key":"R22-6-20210130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1126\/science.280.5362.427","article-title":"Gastrointestinal tract as a major site of CD4 T cell depletion and viral replication in SIV infection.","volume":"280","author":"Veazey","year":"1998","journal-title":"Science"},{"key":"R23-6-20210130","doi-asserted-by":"crossref","first-page":"11708","DOI":"10.1128\/JVI.77.21.11708-11717.2003","article-title":"Severe CD4 T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.","volume":"77","author":"Guadalupe","year":"2003","journal-title":"J Virol"},{"key":"R24-6-20210130","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/QAD.0b013e32833ef7bb","article-title":"Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.","volume":"24","author":"Yukl","year":"2010","journal-title":"AIDS"},{"key":"R25-6-20210130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/QAD.0b013e328344cefb","article-title":"Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy.","volume":"25","author":"Chege","year":"2011","journal-title":"AIDS"},{"key":"R26-6-20210130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-1293.2009.00725.x","article-title":"Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma.","volume":"10","author":"Lorello","year":"2009","journal-title":"HIV Med"},{"key":"R27-6-20210130","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1128\/JVI.77.3.2271-2275.2003","article-title":"In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to 5 copies per milliliter, with a half-life of 6 months.","volume":"77","author":"Di Mascio","year":"2003","journal-title":"J Virol"},{"key":"R28-6-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection.","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"R29-6-20210130","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.0800050105","article-title":"Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.","volume":"105","author":"Palmer","year":"2008","journal-title":"Proc Nat Acad Sci U S A"},{"key":"R30-6-20210130","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/00003495-200969080-00007","article-title":"Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.","volume":"69","author":"Croxtall","year":"2009","journal-title":"Drugs"},{"key":"R31-6-20210130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"R32-6-20210130","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0b013e328323da60","article-title":"Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.","volume":"23","author":"Canducci","year":"2009","journal-title":"AIDS"},{"key":"R33-6-20210130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1468-1293.2008.00628.x","article-title":"Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.","volume":"9","author":"Charpentier","year":"2008","journal-title":"HIV Med"},{"key":"R34-6-20210130","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1097\/QAD.0b013e32832ec4ae","article-title":"The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.","volume":"23","author":"Ferns","year":"2009","journal-title":"AIDS"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e32834e8955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:33:06Z","timestamp":1620970386000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201201140-00006"}},"subtitle":["a randomized controlled trial"],"short-title":[],"issued":{"date-parts":[[2012,1,14]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32834e8955","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,14]]}}}